A systematic review and meta-analysis that included a total of 38 723 participants demonstrated the renoprotective effects of an SGLT2 inhibitor in T2DM patients with eGFRs ranging from 30 to 45 mL/min/1.73 m2 [31]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.